Search details
1.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Gastroenterology
; 158(8): 2123-2138.e8, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32044319
2.
Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease.
Dig Dis Sci
; 64(5): 1142-1149, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30659472
3.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Lancet
; 390(10114): 2779-2789, 2017 12 23.
Article
in English
| MEDLINE | ID: mdl-29096949
4.
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
Am J Gastroenterol
; 113(6): 872-882, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29867173
5.
Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.
Gastrointest Endosc
; 83(1): 188-97.e1-3, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26234693
6.
Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis.
Dig Dis Sci
; 61(10): 2823-2830, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27417565
7.
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
Gastroenterology
; 146(1): 110-118.e3, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24067881
8.
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Gastroenterology
; 146(4): 941-9, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-24361468
9.
Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
Clin Gastroenterol Hepatol
; 13(5): 940-8.e3, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25245624
10.
Adalimumab induces deep remission in patients with Crohn's disease.
Clin Gastroenterol Hepatol
; 12(3): 414-22.e5, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-23856361
11.
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Am J Gastroenterol
; 109(11): 1771-80, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25155227
12.
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 142(2): 257-65.e1-3, 2012 Feb.
Article
in English
| MEDLINE | ID: mdl-22062358
13.
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Gut
; 60(6): 780-7, 2011 Jun.
Article
in English
| MEDLINE | ID: mdl-21209123
14.
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
Eur J Heart Fail
; 11(3): 304-11, 2009 Mar.
Article
in English
| MEDLINE | ID: mdl-19158152
15.
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
Am J Cardiovasc Drugs
; 9(2): 69-79, 2009.
Article
in English
| MEDLINE | ID: mdl-19331435
16.
Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy.
Clin Drug Investig
; 29(4): 215-29, 2009.
Article
in English
| MEDLINE | ID: mdl-19301936
17.
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
Inflamm Bowel Dis
; 25(9): 1522-1531, 2019 08 20.
Article
in English
| MEDLINE | ID: mdl-30753510
18.
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
Inflamm Intest Dis
; 2(4): 228-235, 2018 Jul.
Article
in English
| MEDLINE | ID: mdl-30221150
19.
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Inflamm Bowel Dis
; 24(5): 932-942, 2018 04 23.
Article
in English
| MEDLINE | ID: mdl-29668919
20.
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
JAMA
; 297(17): 1883-91, 2007 May 02.
Article
in English
| MEDLINE | ID: mdl-17473298